[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thalidomide-enhances-clinical-efficacy-of-cetuximab-combined-with-standard-chemotherapy-for-left-colorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thalidomide-enhances-clinical-efficacy-of-cetuximab-combined-with-standard-chemotherapy-for-left-colorectal-cancer":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":5},"100537555",false,"NCT06279351","Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","Inclusion Criteria:\n\n1. Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue\u002Fcytology and genetic testing;\n2. Physical state is good: PS 0-2;\n3. Expected survival of more than 3 months;\n4. Aged 18-75 years old;\n5. Have not received systematic chemotherapy before;\n6. Did not receive cetuximab treatment;\n7. Liver, kidney and bone marrow functions are basically normal;\n8. The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;\n9. Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.\n\nExclusion Criteria:\n\n1. Patients with severe dysfunction of vital organs (heart, liver, kidney);\n2. Patients with other malignant tumors;\n3. Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);\n4. In the active phase of acute or chronic infectious diseases;\n5. People with a clear history of drug allergy or allergic constitution;\n6. Patients participating in other clinical trials;\n7. Other conditions in which the patient was considered inappropriate to participate in the study.","ALL","18 Years","75 Years",{"count":18,"type":19},96,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application.\n2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.",[12],"RECRUITING","2025-07-11",{"date":28,"type":29},"2025-07-14","ACTUAL",{"date":31,"type":29},"2024-08-11",{"date":33,"type":19},"2025-12-31",{"name":35,"class":36},"Xinqiao Hospital of Chongqing","OTHER",""]